Hepatitis C Virus [clinicaltrials_resource:486b8ad3e5e4f9cec5a0262d30c3a87d]
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 [clinicaltrials:NCT00143000]Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. [clinicaltrials:NCT00179413]Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin [clinicaltrials:NCT00194857]Hepatitis C Virus and the Humoral Immune System [clinicaltrials:NCT00219999]Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers [clinicaltrials:NCT00342641]Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin [clinicaltrials:NCT00382798]Management of Hepatitis C in HIV-Infected and Uninfected IDUs [clinicaltrials:NCT00496912]Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus [clinicaltrials:NCT00503347]Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C [clinicaltrials:NCT00633230]clinicaltrials:NCT00671671clinicaltrials:NCT00678587clinicaltrials:NCT00705224Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation [clinicaltrials:NCT00710801]Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 [clinicaltrials:NCT00810758]A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C [clinicaltrials:NCT00814606]Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors [clinicaltrials:NCT00819026]Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State [clinicaltrials:NCT00861458]Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population [clinicaltrials:NCT00894257]clinicaltrials:NCT00896233Japanese Bridging Study Conducted in the United States [clinicaltrials:NCT00947245]PEG-IFN Plus Ribavirin Combination Therapy for Older Patients [clinicaltrials:NCT00956982]Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4 [clinicaltrials:NCT01006031]TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435 [clinicaltrials:NCT01022125]Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin [clinicaltrials:NCT01030432]Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV [clinicaltrials:NCT01040039]clinicaltrials:NCT01046058Drug Interaction Oral Contraceptive Pill (OCP) [clinicaltrials:NCT01063023]TMC435-TiDP16-C112 - Interaction Trial With Antidepressants [clinicaltrials:NCT01090700]clinicaltrials:NCT01091077Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection [clinicaltrials:NCT01097395]TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light [clinicaltrials:NCT01124799]clinicaltrials:NCT01125189TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration [clinicaltrials:NCT01134718]clinicaltrials:NCT01170962clinicaltrials:NCT01188772Ph IIA Study (SOC +/- NS5B) [clinicaltrials:NCT01193361]clinicaltrials:NCT01195181TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir [clinicaltrials:NCT01205139]TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir [clinicaltrials:NCT01241773]Study in Genotype 2/3 Subjects With Chronic Hepatitis C [clinicaltrials:NCT01257204]
condition [clinicaltrials_vocabulary:condition]
Hepatitis C Virus [clinicaltrials_resource:486b8ad3e5e4f9cec5a0262d30c3a87d]
Bio2RDF identifier
486b8ad3e5e4f9cec5a0262d30c3a87d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:486b8ad3e5e4f9cec5a0262d30c3a87d
identifier
clinicaltrials_resource:486b8ad3e5e4f9cec5a0262d30c3a87d
title
Hepatitis C Virus
@en
label
Hepatitis C Virus [clinicaltrials_resource:486b8ad3e5e4f9cec5a0262d30c3a87d]
@en